A number of polymeric materials having useful therapeutic activity have been described for treatment of various conditions such as hyperlipidemia and hyperphosphatemia. Many of these polymeric materials function as non-absorbed ion exchange resins in the digestive tract. Such non-absorbed polymeric materials bind or otherwise sequester a target molecule and facilitate its removal from the body via the gastrointestinal tract. Examples of such resins include: Colestipol and Cholestyramine useful as orally administered cholesterol lowering agents; a variety of aliphatic amine polymers disclosed U.S. Pat. Nos. 5,496,545 and 5,667,775 useful as phosphate binders particularly for removing phosphate from patients suffering from renal failure; and other aliphatic amine polymers disclosed in U.S. Pat. No. 5,624,963, U.S. Pat. No. 5,679,717, WO98/29107 and WO99/22721 useful as cholesterol lowering agents.
Non-absorbed polymer therapeutics have traditionally presented a number of formulation challenges as the dosages are generally very large (gram quantities), and the resins tend to be extremely hydrophilic. The most desirable formulation for oral delivery of a therapeutic is a direct compression tablet formulation. However, not all therapeutics, particularly given the high dose requirements of polymeric ion exchange therapeutics, lend themselves to a tablet formulation. Even if such materials could be rendered into a tablet, it is generally not possible without the significant addition of other materials which assist in the tableting process. Ultimately the addition of any materials other than the active ingredient is undesirable given the dose requirement of the active ingredient. Ideally the tablet should contain as much active ingredient as possible with little else in the way of additional materials such that the tablet is as small as possible and easy to administer to the patient.
In addition, once the polymeric materials are compressed into a tablet, the tablet requires a coating for ease of administration to the patient. It has been discovered that the core polymeric material tends to be very hygroscopic, and thus will swell immediately upon contact with the inside of the mouth. Most coatings contain water, and thus it was believed that coating such tablets with a water-based coating would be impossible because the hygroscopic tablets would swell during the coating process. Thus providing a tablet core comprising a hygroscopic material such that a suitable coating may be used in conjunction with that core, is another significant challenge to providing the polymeric active ingredient in tablet form.
There is a need to provide suitable dosage forms for polymeric ion exchange materials, particularly for hydrophilic aliphatic amine polymers useful as therapeutic agents, which minimize the overall amount of material administered to the patient, which are easy to administer orally, and which are stable upon production and storage.
The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. In a preferred embodiment, the aliphatic amine polymer resin is a cross-linked polyallylamine resin. The aliphatic amine polymer is preferably hydrated. The hydrated polymer can, for example, comprise from about 5% water by weight or greater.
The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating or drying the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet wherein the coating comprises a water based coating.
The FIGURE is a table comprising data showing formulations and responses for sevelamer hydrochloride compressed tablet cores.
A number of polymeric materials having useful therapeutic activity have been discussed above. In particular, aliphatic amine polymers have been disclosed which are useful in methods of lowering the serum phosphate level of a patient and lowering the serum cholesterol level of a patient. For example an epichorohydrin-cross-linked poly(allylamine hydrochloride) resin (U.S. Pat. Nos. 5,496,545 and 5,667,775), also referred to as sevelamer hydrochloride or sevelamer and marketed as RENAGEL®, has been shown to be effective at removing phosphate from human patients suffering from renal failure. Therapeutically effective dosages of sevelamer hydrochloride are large, typically on the order of 4 to 6 grams per day. Consequently, development of a dosage form of this and similar resins which minimizes the amount of excipient material is desirable.
The present invention provides a tablet core comprising at least about 95% by weight of an aliphatic amine polymer. The aliphatic amine polymer resin can be any of the aliphatic amine resins described in U.S. Pat. Nos. 5,496,545; 5,667,775; 5,624,963; 5,703,188; 5,679,717; 5,693,675, 5,607,669; 5,618,530; 5,487,888; and 5,702,696, each of which is hereby incorporated herein by reference in its entirety. Other suitable aliphatic amine polymers are disclosed in U.S. Ser. Nos. 08/670,764; 08/959,471, and 08/979,096, each of which is hereby incorporated by reference herein in its entirety. In a particularly preferred embodiment, the aliphatic amine polymer is polyallylamine, polyvinylamine, poly(diallylamine) or poly(ethyleneimine) or a salt thereof with a pharmaceutically acceptable acid. The aliphatic amine polymer is optionally substituted at one or more nitrogen atoms with an alkyl group or a substituted alkyl group such as a trialkylammonioalkyl group. The aliphatic amine polymer can optionally be cross-linked, for example via a multifunctional monomer or a bridging group which connects two amino nitrogen atoms from two different polymer strands. In a preferred embodiment, the aliphatic amine polymer resin is hydrated. For sevelamer hydrochloride, in particular, the compressibility is strongly dependent upon the degree of hydration (moisture content) of the resin. Preferably, the resin has a moisture content of about 5% by weight or greater, more preferably, the moisture content is from about 5% to about 9% by weight, and most preferably about 7% by weight. It is to be understood that in embodiments in which the polymer resin is hydrated, the water of hydration is considered to be a component of the resin. Thus, in this embodiment, the tablet core comprises at least about 95%, preferably at least about 96%, and more preferably at least about 98% by weight of the hydrated polymer, including the water of hydration.
The tablet can further comprise one or more excipients, such as hardeners, glidants and lubricants, which are well known in the art. Suitable excipients include colloidal silicon dioxide, stearic acid, magnesium silicate, calcium silicate, sucrose, calcium stearate, glyceryl behenate, magnesium stearate, talc, zinc stearate and sodium stearylfumarate. The excipients can represent from 0 to about 5% of the tablet core by weight.
The tablet core of the invention is prepared by a method comprising the steps of: (1) hydrating or drying the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with any excipients to be included in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend using conventional tableting technology.
The invention also relates to a stable, swallowable coated tablet, particularly a tablet comprising a hydrophilic core, such as a tablet comprising an aliphatic amine polymer, as described above. In one embodiment, the coating composition comprises a cellulose derivative and a plasticizing agent. The cellulose derivative is, preferably, hydroxypropylmethylcellulose (HPMC). The cellulose derivative can be present as an aqueous solution. Suitable hydroxypropylmethylcellulose solutions include those containing HPMC low viscosity and/or HPMC high viscosity. Additional suitable cellulose derivatives include cellulose ethers useful in film coating formulations. The plasticizing agent can be, for example, an acetylated monoglyceride such as diacetylated monoglyceride. The coating composition can further include a pigment selected to provide a tablet coating of the desired color. For example, to produce a white coating, a white pigment can be selected, such as titanium dioxide.
In one embodiment, the coated tablet of the invention can be prepared by a method comprising the step of contacting a tablet core of the invention, as described above, with a coating solution comprising a solvent, at least one coating agent dissolved or suspended in the solvent and, optionally, one or more plasticizing agents. Preferably, the solvent is an aqueous solvent, such as water or an aqueous buffer, or a mixed aqueous/organic solvent. Preferred coating agents include cellulose derivatives, such as hydroxypropylmethylcellulose. Typically, the tablet core is contacted with the coating solution until the weight of the tablet core has increased by an amount ranging from about 4% to about 6%, indicating the deposition of a suitable coating on the tablet core to form a coated tablet.
In one preferred embodiment, the solids composition of the coating solution is:
Tablets may be coated in a rotary pan coater as is known in the art or any other conventional coating apparatus such as a column coater or a continuous coater.
Astonishingly, it has been found that an aqueous coating dispersion is suitable as a coating solution for tablets comprising a hygroscopic, or water-swellable substance, such as an aliphatic amine polymer tablet. For example, the coating composition provides a strong, elastic and moisture-permeable coating without causing significant concomitant swelling of the tablet core during the coating process. In a preferred embodiment, the coating composition provides a tablet coating which withstands the swelling and contraction of sevelamer hydrochloride tablets during exposure to varying humidity levels and other known stability tests. Further, the coating composition can be used to coat other aliphatic amine polymer tablets without excessive uptake by the tablet core of water from the coating solution during the coating process.
The present invention also relates to the use of an aliphatic amine polymer as a disintegrant in a tablet. In general, in this embodiment the aliphatic amine polymer is not the active ingredient in the tablet, but is added to the tablet to enhance the rate of disintegration of the tablet following administration. This allows a more rapid release of the active agent or agents. The tablet will generally include the aliphatic amine polymer, one or more active ingredients, such as therapeutic agents (medicaments), and, optionally, one or more additional excipients.
The aliphatic amine polymer can be one of the aliphatic amine polymers disclosed above, such as polyethyleneimine, polyvinylamine, polyallylamine, polydiallylamine or any of the aliphatic amine polymers disclosed in U.S. Pat. Nos. 5,496,545 and 5,667,775 and U.S. Ser. Nos. 08/777,408 and 08/964,498, the teachings of each of which are incorporated herein by reference. In one embodiment, the aliphatic amine polymer is a cross-linked polyallylamine or a salt thereof with a pharmaceutically acceptable acid. Preferably, the aliphatic amine polymer is an epichlorohydrin-cross-linked polyallylamine or salt thereof with a pharmaceutically acceptable acid, such as sevelamer or sevelamer hydrochloride.
The tablet which includes an aliphatic amine as a disintegrant will, generally, include a sufficient amount of the aliphatic amine polymer to effectively enhance the rate of tablet disintegration under conditions of use. For example, if the tablet is an oral doseage form and it is desired that the tablet disintegrate in the stomach of the patient, the tablet should include a sufficient amount of the polymer to enhance the disintegration rate of the tablet under the conditions encountered in the stomach. The appropriate amount of the polymer to be included in the tablet can be determined by one skilled in the art using known methods. Typically, the polymer, the active ingredient or ingredients and any additional fillers or excipients are combined by mixing, and the resulting mixture is compressed to form a tablet using conventional methods. The tablet core formed in this way can then be coated, for example, as described above, or by other methods and other coating compositions which are known in the art and suitable for the intended use of the tablet.
In one embodiment, the tablet which includes an aliphatic amine polymer as a disintegrant is intended for administration in vivo, for example, to a patient, such as a human. Preferably, the tablet is intended to be administered orally. In this embodiment, the active ingredient or ingredients will be a therapeutic or diagnostic agent. The tablet can also be intended for use in vitro, for example, to deliver an active ingredient to an aqueous environment, such as a swimming pool.
The invention will now be described in detail by reference to the following examples.
Preparation of Tablet Cores
400 mg sevelamer hydrochloride tablet cores were prepared from a blend consisting of 5000.0 g sevelamer hydrochloride, 50.0 g colloidal silicon dioxide, NF (Aerosil 200) and 50.0 g stearic acid. The sevelamer hydrochloride was hydrated to moisture content of 6% by weight. The blend was prepared by passing the sevelamer hydrochloride and colloidal silicon dioxide through a #20 mesh screen, transferring the mixture to a 16 quart PK blender and blending for five minutes. The stearic acid was then passed through an oscillator equipped with a #30 mesh screen, transferred into the 16 quart PK blender and blended for five minutes with the sevelamer hydrochloride/colloidal silicon dioxide mixture. The resulting blend was discharged into a drum and weighed. The final blend was then compressed on a 16 station Manesty B3B at 4 tons pressure using 0.280″×0.620″ punches to give tablet cores with an average weight of 434 mg. The resulting tablets consisted of 425 mg 6% hydrated sevelamer hydrochloride (equivalent to 400 mg anhydrous sevelamer hydrochloride), 4.25 mg colloidal silicon dioxide and 4.25 mg stearic acid.
800 mg sevelamer hydrochloride tablet cores were prepared from 19.0 kg sevelamer hydrochloride, 0.19 kg colloidal silicon dioxide, and 0.19 kg stearic acid. The sevelamer hydrochloride had a moisture content of 6% by weight. The blend was prepared by passing the sevelamer hydrochloride and colloidal silicon dioxide through a #20 mesh screen, transferring the mixture to a PK blender and blending for five minutes. The stearic acid was then passed through an oscillator equipped with a #30 mesh screen, transferred into the PK blender and blended for five minutes with the sevelamer hydrochloride/colloidal silicon dioxide mixture. The resulting blend was then discharged into a drum and weighed. The final blend was then compressed in on a 16 station Manesty B3B at 4 tons pressure using 0.3125″×0.750″ punches to give tablets with an average weight of 866 mg. The resulting tablets consisted of 850 mg 6% hydrated sevelamer hydrochloride (equivalent to 800 mg anhydrous sevelamer hydrochloride), 8.0 mg colloidal silicon dioxide and 8.0 mg stearic acid.
Characterization of Tablet Cores
The tablets prepared as described above were white to off-white, oval shaped, compressed tablets. The variation of the tablets prepared from each blend with respect to weight, thickness, friability, hardness, disintegration time and density was assessed. Standard methods in the art were employed for each of the measurements. The results, (not shown), indicate that the hardness, friability, thickness, and disintegration behavior of the sevelamer hydrochloride tablets all met industry-standard criteria.
Compressed core tablets prepared as described in Example 1 were coated in a coating pan with an aqueous coating solution having a solids composition comprising:
The coating solution was applied to the compressed cores until a weight gain of approximately 4 to 6% was achieved. Stability studies—controlled room temperature, accelerated conditions, freeze/thaw and photosensitivity—for the coated sevelamer hydrochloride tablets were conducted in accordance with those procedures known in the art and described in the following references: International Committee on Harmonization (ICH) guidance “Q1A-Stability Testing of New Drug Substances and Products” (June 1997); ICH “Q1B-Guidelines for the Photostability Testing of New Drug Substances and Products” (November 1996); and ICH guidance “Q1C-Stability Testing for New Dosage Forms” (November 1996. The results (not shown) indicate that the coated tablets all met industry standard criteria.
In order to maintain consistently acceptable compressed tablet on a per batch basis, a number of correlative tests were performed in order to determine which factors most strongly impact the quality and integrity of the tablets. Studies such as weight variation, tablet hardness, friability, thickness, disintegration time, among others are known to those skilled in the art and are described in the United States Pharmacopeia (U.S.P.). “Hardness” means the measure of the force (measured herein in Newtons) needed to fracture a tablet when such tablet is placed lengthwise on a Hardness Tester. “Friability” is the measure of the mechanical strength of the tablet needed to withstand the rolling action of a coating pan and packaging. It is measured using a friabiliator. “Thickness” is the measure of the height of the tablet using a micrometer. “Disintegration Time” is the time necessary for the tablet to break apart in an appropriate solution at 37° C. and is measured in minutes.
Attainment of appropriate hardness (150-170 N hardness range) and friability (no more than 0.8%) is important to the success of the formulation. Having tablets with high hardness and low friability is particularly important when the tablets are to be coated as is the case with sevelamer hydrochloride tablets.
The FIGURE provides a table listing several different sevelamer hydrochoride tablet core formulations that vary by a number of factors including (actual) moisture content, and compression force used, excipient content among other variations. The data in
The FIGURE indicates that the most important factor affecting the processing and performance characteristics of compressed tablets is the moisture content. All formulations provided good flow with little weight variation throughout the entire range of compositions. In addition, disintegration times were less than 5 minutes across the range of compositions. Thus, it appears that moisture content and compression force provide the most appropriate factors on which to establish operating ranges for hardness and friability.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
This application is a continuation of U.S. application Ser. No. 14/481,071, filed Sep. 9, 2014, which is a continuation of U.S. application Ser. No. 13/467,448, filed May 9, 2012, which is a continuation of U.S. application Ser. No. 12/461,143, filed Aug. 3, 2009, now U.S. Pat. No. 8,187,631 issued on May 29, 2012, which is a continuation of U.S. application Ser. No. 11/196,799, filed Aug. 3, 2005, which is a further continuation of U.S. application Ser. No. 10/785,322, filed Feb. 24, 2004, which is a continuation of U.S. application Ser. No. 09/691,429, filed Oct. 18, 2000, now U.S. Pat. No. 6,733,780 issued on May 11, 2004, which claims the benefit of U.S. Provisional Application No. 60/160,258, filed Oct. 19, 1999, and U.S. Provisional Application No. 60/174,227, filed Jan. 3, 2000. The foregoing related applications, in their entirety, are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
2426125 | Steiner | Aug 1947 | A |
2456428 | Parker | Dec 1948 | A |
2463824 | Steiner et al. | Mar 1949 | A |
3104205 | Hainer et al. | Sep 1963 | A |
3308020 | Tennant et al. | Mar 1967 | A |
3332841 | Ainsworth et al. | Jul 1967 | A |
3383236 | Brindamour | May 1968 | A |
3431138 | Zingerman et al. | Mar 1969 | A |
3539380 | Johnson et al. | Nov 1970 | A |
3624209 | Granatek et al. | Nov 1971 | A |
3980770 | Ingelman et al. | Sep 1976 | A |
4016209 | Wagner et al. | Apr 1977 | A |
4071478 | Shen et al. | Jan 1978 | A |
4115537 | Driscoll et al. | Sep 1978 | A |
4143130 | Imondi et al. | Mar 1979 | A |
4172120 | Todd et al. | Oct 1979 | A |
4181718 | Mason et al. | Jan 1980 | A |
4183918 | Asher et al. | Jan 1980 | A |
4205064 | Wagner et al. | May 1980 | A |
4211763 | Marshall et al. | Jul 1980 | A |
4247393 | Wallace | Jan 1981 | A |
4264573 | Powell et al. | Apr 1981 | A |
4302440 | John et al. | Nov 1981 | A |
4341563 | Kurihara et al. | Jul 1982 | A |
4344993 | Schmidt et al. | Aug 1982 | A |
4439419 | Vecchio | Mar 1984 | A |
4504640 | Harada et al. | Mar 1985 | A |
4507466 | Tomalia et al. | Mar 1985 | A |
4518433 | McGinley et al. | May 1985 | A |
4528184 | Kurono et al. | Jul 1985 | A |
4539198 | Powell et al. | Sep 1985 | A |
4543370 | Porter et al. | Sep 1985 | A |
4605701 | Harada et al. | Aug 1986 | A |
4631305 | Guyer et al. | Dec 1986 | A |
4762524 | Chambers et al. | Aug 1988 | A |
4849227 | Cho | Jul 1989 | A |
4853437 | Lukach et al. | Aug 1989 | A |
4871779 | Killat et al. | Oct 1989 | A |
4895621 | Hassler | Jan 1990 | A |
4956182 | Bequette et al. | Sep 1990 | A |
4983398 | Gaylord et al. | Jan 1991 | A |
4983399 | Maish | Jan 1991 | A |
5053423 | Liu | Oct 1991 | A |
5055197 | Albright et al. | Oct 1991 | A |
5073380 | Babu et al. | Dec 1991 | A |
5108767 | Mulchandani et al. | Apr 1992 | A |
5194464 | Itoh et al. | Mar 1993 | A |
5262167 | Vegesna et al. | Nov 1993 | A |
5302531 | Bauer | Apr 1994 | A |
5373052 | Fukuda et al. | Dec 1994 | A |
5374422 | St. Pierre et al. | Dec 1994 | A |
5376396 | Clark | Dec 1994 | A |
5401515 | Woodard et al. | Mar 1995 | A |
5414068 | Bliem et al. | May 1995 | A |
5428112 | Ahlers et al. | Jun 1995 | A |
5430110 | Ahlers et al. | Jul 1995 | A |
5447726 | Nomura | Sep 1995 | A |
5455047 | Bequette et al. | Oct 1995 | A |
5462730 | McTaggart et al. | Oct 1995 | A |
5487888 | Mandeville et al. | Jan 1996 | A |
5496545 | Holmes-Farley et al. | Mar 1996 | A |
5520932 | McCurdy et al. | May 1996 | A |
5530092 | Meijer et al. | Jun 1996 | A |
5561214 | Yeske et al. | Oct 1996 | A |
5607669 | Mandeville, III et al. | Mar 1997 | A |
5610268 | Meijer et al. | Mar 1997 | A |
5618530 | Mandeville, III et al. | Apr 1997 | A |
5624963 | Mandeville, III et al. | Apr 1997 | A |
5654003 | Fuisz et al. | Aug 1997 | A |
5667775 | Holmes-Farley et al. | Sep 1997 | A |
5679717 | Mandeville, III et al. | Oct 1997 | A |
5686106 | Kelm et al. | Nov 1997 | A |
5693675 | Mandeville, III et al. | Dec 1997 | A |
5702696 | Mandeville, III et al. | Dec 1997 | A |
5703188 | Mandeville, III et al. | Dec 1997 | A |
5709880 | Del Corral et al. | Jan 1998 | A |
5718920 | Notenbomber | Feb 1998 | A |
5747067 | Auguello et al. | May 1998 | A |
5750148 | Maruyama et al. | May 1998 | A |
5807582 | Cha | Sep 1998 | A |
5814336 | Kelm et al. | Sep 1998 | A |
5840339 | Kunin | Nov 1998 | A |
5840766 | Mandeville, III et al. | Nov 1998 | A |
5900475 | Mandeville, III et al. | May 1999 | A |
5919832 | Mandeville, III et al. | Jul 1999 | A |
5959069 | Gluck et al. | Sep 1999 | A |
5969090 | Mandeville, III et al. | Oct 1999 | A |
5985938 | Holmes-Farley et al. | Nov 1999 | A |
6022533 | Goto et al. | Feb 2000 | A |
6034129 | Mandeville, III et al. | Mar 2000 | A |
6037444 | Rannard et al. | Mar 2000 | A |
6083495 | Holmes-Farley et al. | Jul 2000 | A |
6083497 | Huval et al. | Jul 2000 | A |
6090411 | Pillay et al. | Jul 2000 | A |
6149938 | Bonadeao et al. | Nov 2000 | A |
6177478 | Holmes-Farley et al. | Jan 2001 | B1 |
6180754 | Stutts et al. | Jan 2001 | B1 |
6187897 | Kawashima et al. | Feb 2001 | B1 |
6190650 | Matthews et al. | Feb 2001 | B1 |
6203785 | Holmes-Farley et al. | Mar 2001 | B1 |
6248318 | Huval et al. | Jun 2001 | B1 |
6264937 | Mandeville, III et al. | Jul 2001 | B1 |
6274713 | Sieving et al. | Aug 2001 | B1 |
6281252 | Holmes-Farley et al. | Aug 2001 | B1 |
6284275 | Chen | Sep 2001 | B1 |
6335402 | Mihan et al. | Jan 2002 | B1 |
6362266 | Buchholz et al. | Mar 2002 | B1 |
6383518 | Matsuda et al. | May 2002 | B1 |
6423754 | Holmes-Farley et al. | Jul 2002 | B1 |
6509013 | Holmes-Farley et al. | Jan 2003 | B1 |
6534600 | Dvornic et al. | Mar 2003 | B2 |
6566407 | Holmes-Farley et al. | May 2003 | B2 |
6600011 | McDonnell et al. | Jul 2003 | B2 |
6605270 | Mandeville et al. | Aug 2003 | B1 |
6696087 | Matsuda et al. | Feb 2004 | B2 |
6726905 | Mandeville, III et al. | Apr 2004 | B1 |
6733780 | Tyler et al. | May 2004 | B1 |
6844372 | Goto et al. | Jan 2005 | B2 |
6858203 | Holmes-Farley et al. | Feb 2005 | B2 |
6908609 | Simon et al. | Jun 2005 | B2 |
7014846 | Holmes-Farley et al. | Mar 2006 | B2 |
7019085 | Albright | Mar 2006 | B2 |
7081509 | Wagner et al. | Jul 2006 | B2 |
7087223 | Goto et al. | Aug 2006 | B2 |
7101960 | Mandeville, III et al. | Sep 2006 | B2 |
7220406 | Burke | May 2007 | B2 |
7335795 | Chang et al. | Feb 2008 | B2 |
7342083 | Chang et al. | Mar 2008 | B2 |
7385012 | Chang et al. | Jun 2008 | B2 |
7449605 | Chang et al. | Nov 2008 | B2 |
7459151 | Holmes-Farley et al. | Dec 2008 | B2 |
7459502 | Connor et al. | Dec 2008 | B2 |
7589238 | Connor et al. | Sep 2009 | B2 |
7638524 | Huval et al. | Dec 2009 | B2 |
7985418 | Bhagat et al. | Jul 2011 | B2 |
8808738 | Bhagat et al. | Aug 2014 | B2 |
9095509 | Bhagat et al. | Aug 2015 | B2 |
20020122786 | Matsuda et al. | Feb 2002 | A1 |
20020054903 | Tyler et al. | May 2002 | A1 |
20020114774 | Fitzpatrick et al. | Aug 2002 | A1 |
20020159968 | Petersen et al. | Oct 2002 | A1 |
20020160050 | Elema et al. | Oct 2002 | A1 |
20020168333 | Burke | Nov 2002 | A1 |
20020182168 | Holmes-Farley et al. | Dec 2002 | A1 |
20020187120 | Holmes-Farley et al. | Dec 2002 | A1 |
20020187121 | Burke | Dec 2002 | A1 |
20030003113 | Lewandowski | Jan 2003 | A1 |
20030039627 | Holmes-Farley et al. | Feb 2003 | A1 |
20030049226 | Burke et al. | Mar 2003 | A1 |
20030086898 | Holmes-Farley et al. | May 2003 | A1 |
20030133902 | Holmes-Farley et al. | Jul 2003 | A1 |
20030161875 | Murpani et al. | Aug 2003 | A1 |
20030175349 | Garg et al. | Sep 2003 | A1 |
20030180250 | Chauhan et al. | Sep 2003 | A1 |
20030199090 | Monahan et al. | Oct 2003 | A1 |
20030215585 | Bunick | Nov 2003 | A1 |
20040019020 | Jozefiak et al. | Jan 2004 | A1 |
20040022844 | Hasenzahl et al. | Feb 2004 | A1 |
20040120922 | Burke | Jun 2004 | A1 |
20040166156 | Tyler et al. | Aug 2004 | A1 |
20040170695 | Elama et al. | Sep 2004 | A1 |
20040185111 | Rubino et al. | Sep 2004 | A1 |
20040191209 | Oba | Sep 2004 | A1 |
20040191212 | Holmes-Farley et al. | Sep 2004 | A1 |
20050084476 | Goto et al. | Apr 2005 | A1 |
20050096438 | Chang et al. | May 2005 | A1 |
20050123614 | Kim et al. | Jun 2005 | A1 |
20050131138 | Connor et al. | Jun 2005 | A1 |
20050131161 | Mandeville, III et al. | Jun 2005 | A1 |
20050147580 | Connor et al. | Jul 2005 | A1 |
20050165190 | Chang et al. | Jul 2005 | A1 |
20050208095 | Hunter et al. | Sep 2005 | A1 |
20050209423 | Chang et al. | Sep 2005 | A1 |
20050220752 | Charmot et al. | Oct 2005 | A1 |
20050220889 | Charmot et al. | Oct 2005 | A1 |
20050220890 | Charmot et al. | Oct 2005 | A1 |
20050239901 | Chang et al. | Oct 2005 | A1 |
20050260236 | Tyler et al. | Nov 2005 | A1 |
20050282010 | Xu | Dec 2005 | A1 |
20060024336 | Charmot et al. | Feb 2006 | A1 |
20060024368 | Fassihi et al. | Feb 2006 | A1 |
20060029663 | Uchida et al. | Feb 2006 | A1 |
20060034914 | Tyler et al. | Feb 2006 | A1 |
20060043984 | Miller et al. | Mar 2006 | A1 |
20060047086 | Albright et al. | Mar 2006 | A1 |
20060054914 | Hsian Yi | Mar 2006 | A1 |
20060088592 | Choi et al. | Apr 2006 | A1 |
20060116391 | Horbury et al. | Jun 2006 | A1 |
20060134225 | Moerck et al. | Jun 2006 | A1 |
20060171916 | Holmes-Farley et al. | Aug 2006 | A1 |
20060177415 | Burke | Aug 2006 | A1 |
20060239959 | Holmes-Farley et al. | Oct 2006 | A1 |
20060251614 | Bhagat et al. | Nov 2006 | A1 |
20060258812 | Gopalkrishna et al. | Nov 2006 | A1 |
20060292192 | Hasenzahl et al. | Dec 2006 | A1 |
20070035313 | Wuersch et al. | Feb 2007 | A1 |
20070059277 | Bhagat et al. | Mar 2007 | A1 |
20070071715 | Deluca et al. | Mar 2007 | A1 |
20070094779 | Dauphin | May 2007 | A1 |
20070098678 | Bhagat et al. | May 2007 | A1 |
20070110707 | Ravi | May 2007 | A1 |
20070155950 | Mandeville, III et al. | Jul 2007 | A1 |
20070190135 | Matsuda et al. | Aug 2007 | A1 |
20070224283 | Chang et al. | Sep 2007 | A1 |
20080014288 | Huval et al. | Jan 2008 | A1 |
20080107737 | Chang et al. | May 2008 | A1 |
20080226735 | Moerck et al. | Sep 2008 | A1 |
20080292697 | Tyler et al. | Nov 2008 | A1 |
20080299199 | Bar-Shalom et al. | Dec 2008 | A1 |
20150104510 | Bhagat et al. | Apr 2015 | A1 |
20160113961 | Bhagat et al. | Apr 2016 | A1 |
Number | Date | Country |
---|---|---|
689797 | Apr 1998 | AU |
656 535 | Jul 1986 | CH |
4010271 | Oct 1991 | DE |
0162388 | Nov 1985 | EP |
0375350 | Jun 1990 | EP |
0379161 | Jul 1990 | EP |
0449151 | Oct 1991 | EP |
0534304 | Mar 1993 | EP |
0605757 | Jul 1994 | EP |
0737759 | Oct 1996 | EP |
0997148 | May 2000 | EP |
1153940 | Nov 2001 | EP |
1210935 | Jun 2002 | EP |
1304104 | Apr 2003 | EP |
0211991 | Mar 2007 | EP |
2217010 | Sep 1974 | FR |
2232563 | Jan 1975 | FR |
0929391 | Jun 1963 | GB |
1238597 | Jul 1971 | GB |
1470538 | Apr 1977 | GB |
2036048 | Nov 1978 | GB |
2391730 | Dec 1978 | GB |
1573487 | Aug 1980 | GB |
2090605 | Jul 1982 | GB |
2276170 | Sep 1994 | GB |
2169356 | Jul 2000 | GB |
50-34095 | Feb 1975 | JP |
58079022 | May 1983 | JP |
60152424 | Aug 1985 | JP |
62-132830 | Jun 1987 | JP |
4-503962 | Mar 1990 | JP |
5-244915 | Sep 1993 | JP |
6-321786 | Nov 1994 | JP |
10-330269 | Dec 1998 | JP |
10316576 | Dec 1998 | JP |
2000178182 | Jun 2000 | JP |
2006-008637 | Jan 2006 | JP |
7401543 | Aug 1974 | NL |
7603653 | Oct 1976 | NL |
1808015 | Apr 1993 | RU |
WO 1990002148 | Mar 1990 | WO |
WO 1992010522 | Jun 1992 | WO |
WO 1993000915 | Jan 1993 | WO |
WO 1993005793 | Jan 1993 | WO |
WO 1994019379 | Jan 1994 | WO |
WO 1994004596 | Mar 1994 | WO |
WO 1994027620 | Dec 1994 | WO |
WO 1994027621 | Dec 1994 | WO |
WO 1995005184 | Feb 1995 | WO |
WO 1996021454 | Jul 1996 | WO |
WO 1996025440 | Aug 1996 | WO |
WO 1997049771 | Dec 1997 | WO |
WO 1998042355 | Oct 1998 | WO |
WO 1998044933 | Oct 1998 | WO |
WO 1999022721 | May 1999 | WO |
WO 2000022008 | Apr 2000 | WO |
WO 2002085378 | Oct 2002 | WO |
WO 2004099288 | Nov 2004 | WO |
WO 2005021000 | Mar 2005 | WO |
WO 2005041902 | May 2005 | WO |
WO 2005065291 | Jul 2005 | WO |
WO 2005072752 | Aug 2005 | WO |
WO 2006022759 | Mar 2006 | WO |
WO 2006050314 | May 2006 | WO |
WO 2006050315 | May 2006 | WO |
WO 2007035313 | Mar 2007 | WO |
Entry |
---|
Bhadra, D. et al., “Glycodendrimeric Nanoparticulate Carriers of Primaquine Phosphate for Liver Targeting” International Journal of Pharmaceutics, 295 (Mar. 2005) 221-233. |
Burt, Helen, et al., “Ion-Exchange Resins as Potential Phosphate-Binding Agents for Renal Failure Patients: Effect of the Physiochemical Properties of Resins on Phosphate and Bile Salt Binding,” Journal of Pharmaceutical Sciences, vol. 76, No. 5 (May 1987) pp. 379-383. |
C and C, Product Catalog, Manesty B3B Rotary Tablet Presses (Product# manesty-b3b-16) downloaded online, Mar. 5, 2014. |
Caramella, Carla et al. “Experimental Evidence of Disintegration Mechanisms” Acta Pharm. Technol., 35:1 (1989) 30-33. |
Chertow, Glenn M. et al. “The Effects of Sevelamer and Calcium Acetate on Proxies of Atherosclerotic and Arteriosclerotic Vascular Disease in Hemodialysis Patients” Am. J. Nephrol., 23:5 (2003) 307-314. |
De Brabander-Van Den Berg, Ellen M. M. et al., “Poly(propylenimin)-Dendrimere: Synthese in gröβerem Maβstab durch heterogen katalysierte Hydrierungen” Angew. Chem. (1993) 1370-1372. [in German only]. |
Delmez, James A., et al., “Hyperphosphatemia: Its Consequences and Treatment in Patients with Chronic Renal Disease,” American Journal of Kidney Diseases, vol. XIX, No. 4 (1992) pp. 303-317. |
Duncan, Ruth et al., “Dendrimer biocompatibility and toxicity” Advanced Drug Delivery Reviews, 57 (2005) 2215-2237. |
Emmett, Michael, et al., “Calcium Acetate Control of Serum Phosphorus in Hemodialysis Patients,” American Journal of Kidney Diseases, vol. XVII, No. 5 (1991) pp. 544-550. |
Examination Report dated Jan. 20, 2011 for corresponding Australian Application No. 2006292672. |
Examination Report dated Sep. 29, 2010 for Brazilian Application No. PI 0015061-4. |
Examination Report dated Nov. 8, 2010 for Japanese Application No. 2001-531357. |
Ferrari, F. et al. “Investigation on Bonding and Distintegration Properties of Pharmaceutical Materials” International Journal of Pharmaceutics, 136 (1996) 71-79. |
Gao, C., “Hyperbranched polymers made from A2, 82 and BB′2 type monomers, 2. Preparation of hyperbranched copoly(sulfone-amine)s by polyaddition of N-ethylethylenediamine and piperazine to divinylsulfone” Polymer (2001), 42(8), 3437-3443. |
Gao, C., “Preparation of Water Soluble hyperbranched poly(sulfone-amine)s by polyaddition of N-ethylethylenediamine to divinyl sulfone” Polymer (2001), 42(18), 7603-7610. |
Gao, Chao, “Hyperbranched copolymers made from A2, B2 and BB′2 type monomers (iv). Copolymerization of divinyl sulfone with 4,4′-trimethylenedipiperidine and N-ethylethylenediamine” Science in China, Series B: Chemistry (2001), 44(2), 207-215. |
Gao, Chao, “Hyperbranched copolymers made from A2, B2 and BB′2 type monomers, 3a: comparison of copoly(sulfone-amine)s containing piperazine and 4,4′-trimethylenedipiperidine units” Macromolecular Chemistry and Physics (2001), 202(15), 3035-3042. |
Gao, Chao, “Hyperbranched polymers made from A2- and BB2′-type monomers; 3. Polyaddition of N-methyl 1,3-propanediamine to divinyl sulfone” Macromolecular Chemistry and Physics (2001), 202(12), 2623-2629. |
Gao, Chao, “Polyaddition of B2 and BB′2 Type Monomers to A2 Type Monomer. 1. Synthesis of Highly Branched Copoly(sulfon-amine)s” Macromolecules (2001), 34(2), 156-161. |
Gao, Chao, “Synthesis of hyperbranched polymers from commercially available A2 and BB′2 type monomers” Chemical Communications (Cambridge), 1 (2001) 107-108. |
Ghosh, J.P., et al., “Preparation and Properties of a New Chelating Resin Containing 2-Nitroso-1-naphthol,” Talanta, vol. 28 (1981) pp. 957-959. |
Hammouda, Y. et al. “The Use of Sodium Chloride as a Directly Compressible Filler in Therapeutic Tablets” Pharm. Ind., 37:5 (1975) 361-363. |
Hobson, Lois J., et al. “Poly(amidoamine) Hyperbranched Systems:Synthesis, Structure and Characterization” Polymer, 40 (1999) 1279-1297. |
Huval, Chad C. et al., “Syntheses of hydrophobically modified cationic hydrogels by copolymerization of alkyl substituted diallylamine monomers and their use as bile acid sequestrants” European Polymer Journal, 40 (2004) 693-701. |
International Search Report dated Apr. 12, 2007 for corresponding PCT/US2006/035370. |
International Search Report dated Apr. 27, 2006 for PCT/US2005/039366. |
Jansen, Johan F.G.A. et al. “The Dendritic Box: Shape-Selective Liberation of Encapsulated Guests” J. Am. Chem. Soc., 117 (1995) 4417-4418. |
Janssen, H.M. et al, “The Synthesis and Characterization of Dendritic Molecules” Eindhoven University of Technology [No date available]. |
Jayamurugan, Govindasamy, et al., “Synthesis of Large Generation poly(propul ether imine) (PETIM) Dendrimers” Tetrahedron, 62 (2006) 9582-9588. |
Katopodis, K. P. et al. “Effectiveness of Aluminum Hydroxide Timing Administration in Relation to Meals in Controlling Hyperphosphatemia in Dialysis Patients” The International Journal of Artificial Organs, 28:8 (2005) 803-807. |
Klapper, Marcus et al., “Poly(methylene amine): A Polymer with the Maximum Possible Number of Amino Groups on a Polymer Backbone” Angew. Chem. Int. Ed., 42 (2003) 4687-4690 (XP002456407). |
Koç, Fikret, et al. “Highly Regioselective Synthesis pf Amino-Functionalized Dendritic PolyGlycerols by a One Pot Hydroformylation/Reductive Amination Sequence” J. Org. Chem., 70 (2005) 2021-2025. |
Kremer, Michael, et al., “Pore-Size Distributions of Cationic Polyacrylamide Hydrogels Varying in Initial Monomer Concentration and CrossInker/Monomer Ratio” Macromolecules, 27 (1994) 2965-2973. |
Kuga, Shigenori, “Pore Size Ditribution Analysis of Gel Substances by Size Exclusion Chromatography” J. Chromatography, 206 (1981) 449-461. |
Lin, Shan-Yang et al. “Influence of Excipients, Drugs, and Osmotic Agent in the Inner Core on the Time-Controlled Disintegration of Compression-Coated Ethylcellulose Tablets” Journal of Pharmaceutical Sciences, 91:9 (Sep. 2002) 2040-2046. |
Mai, Martin L., et al., “Calcium acetate, an effective phosphorus binder in patients with renal failure,” Kidney International, vol. 36 (1989) pp. 690-695. |
Maroni, Bradley J. et al. “Renal Bioreplacement Therapy is Associated with a Reduction in Mortality in Patients with Acute Renal Failure: Results of a Randomized, Multi-Center, Phase II Trial” ERA-EDTA: Abstract #551794 (2006). |
Mattsson, S. et al. “Formulation of High Tensile Strength Rapidly Disintegrating Tablets Evaluation of the Effect of Some Binder Properties” S.T.P. Pharma Sciences, 11:3 (2001) 211-220. |
McGary, T.J., et al., “Polycation as an Alternative Osmotic Agent and Phosphate Binder in Peritoneal Dialysis,” Uremia Investigation, vol. 8, No. 2 (1984-85) pp. 79-84. |
McGraw-Hill Dictionary of Scientific and Technical Terms, Third Ed., The Nikkan Kogyo Shimbu, LTD., 1997, p. 54. |
Mitchell, Karen et al. “The Influence of Additives on the Cloud Point, Disintegration and Dissolution of Hydroxypropylmethylcellulose Gels and Matrix Tablets” International Journal of Pharmaceutics, 66 (1990) 233-242. |
Mourey, T. H., et al., “Unique Behavior of Dendritic Molecules: Intrinsic Viscosity of Polyether Dendrimers” Macromolecules, 25 (1992) 2401-2406. |
Munson, Paul L., “Studies on the Role of the Parathyroids in Calcium and Phosphorus Metabolism,” Annals New York Academy of Sciences (Jun. 1993) pp. 776-795. |
Newkome, George R. et al., “Improved Synthesis of an Ethereal Tetraamine Core for Dendrimer Construction” J. Org. Chem., 67 (2002) 3957-3960. |
Pavlov, G. M. et al. “Molecular Characteristics of Poly(propylene imine) Dendrimers as Studied with Translational Diffusion and Viscometry” Colloid. Polym. Sci., 280 (2002) 416-423. |
Pérignon, Nelly et al., “Formation and Stabilization in Water of Metal Nanoparticles by a Hyperbranched Polymer Chemically Analgous to PAMAM Dendrimers” Chem Mater., 16 (2004) 4856-4858. |
Petrariu, I., et al., “Hofmann degradation in quaternary basic ammonium polymers: I. Degradation of the linear and crosslined basic benzylic polyelectrolytes in alkaline media,” Majer. Plast. (Bucharest), vol. 9, No. 9 (1972) pp. 467-472. |
Physicians' Desk Reference “Renagel”, 2012. |
Physicians' Desk Reference, Consult 1992 Supplements for Revisions—“Amphojel® Suspension Tablets”, p. 2429. |
Physicians' Desk Reference, Consult 1992 Supplements for Revisions—“Phoslo® Calcium Acetate Tablets”. |
Proceedings of the American Chemical Society Division of Polymeric Materials: Science and Engineering, Boston, Massachusetts, vol. 62 (1990) pp. 259-263. |
“Renvela: sevelamer carbonate” Prescribing Information, Genzyme Corporation, Nov. 2007. |
Rosenbaum, D.P, et al., “Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats” Nephrology Dialysis Transplantation, vol. 12 (1997) 961-964. |
Salusky, I.B., et al., “Aluminum Accumulation During Treatment with Aluminum Hydroxide and Dialysis in Children and Young Adults with Chronic Renal Disease,” The New England Journal of Medicine, vol. 324, No. 8 (1991) pp. 527-531. |
Sarker, Dipak K. et al. “Restoration of Protein Foam Stability Through Electrostatic Propylene Glycol Alginate-Mediated Protein—Protein Interactions,” Colloids and Surfaces B: Biointerfaces, 15 (1999) 203-213. |
Schatzlein, Andreas G. et al., “Preferential liver gene expression with polypropylenimine dendrimers” Journal of Controlled Release, 101 (2005) 247-258. |
Schulz, W. “Brief Evaluation: Sevelamer Hydrochloride” Drug, Therapy Criticism, Hans Marseille Publishers GmbH, Munich, Issue 3 (2001) 621-626. |
Selmeczi, B. et al. “Investigations of the Influence of Some Novel Auxiliary Agents on the Physical Properties of Tablets” Pharmaceutical Technological Institute of the Medical University of Szeged (Hungary), [No date available]. |
Shao, Lu et al., “Transport properties of cross-linked polyimide membranes induced by different generations of diaminobutane (DAB) dendrimers” Journal of Membrane Science, 238 (2004) 153-163. |
Shkinev, V.M., et al., “Anion exchange extraction and enrichment from aqueous solutions by quaternary ammonium reagents,” Solvent Extraction and Ion Exchange, vol. 7, No. 3 (1989) pp. 499-510. |
Slatopolsky, Eduardo, et al., “Calcium Carbonate as a Phosphate Binder in Patients with Chronic Renal Failure Undergoing Dialysis,” The New England Journal of Medicine, vol. 315, No. 3 (1986) pp. 157-161. |
Soltero, Richard et al. “The Effects of PH. Ionic Concentration and Ionic Species of Dissolution Media on the Release Rates of Quinidine Gluconate Sustained Release Dosage Forms” Drug Development and Industrial Pharmacy, 17:1 (1991) 113-140. |
Stasko, Nathan A. et al., “Dendrimers as a Scaffold for Nitric Oxide Release” J. Am. Chem. Soc., 128 (2006) 8265-8271. |
Sugimoto, H., et al.; Journal of Food Processing and Preservations, 1981, 5:83-93. |
Tirkkonen, Sirpa et al. “Enhancement of Drug Release from Ethylcellulose Microcapsules Using Solid Sodium Chloride in the Wall” International Journal of Pharmaceutics, 88 (1992) 39-51. |
Tirkkonen, Sirpa et al. “Release of Indomethacin from Tabletted Ethylcellulose Microcapsules” International Journal of Pharmaceutics, 92 (1993) 55-62. |
Ullmanns Encyklopadie der technischen Chemie—Band 19: Polyolefine (1980) pp. 167-178. |
Warshawsky, A., “Ion Exchange and Sorption Processes in Hydrometallurgy”, Critical Reports on Applied Chemistry, vol. 19: Chapter 4: Chelating Ion Exchangers, M. Streat & D. Naden (Eds.), John Wiley & Sons (1987) pp. 166-225. |
Winston, Anthony and Kirchner, Darrell, “Hydroxamic Acid Polymers. Effect of Structure of the Selective Chelation of Iron in Water,” Macromolecules, vol. 11, No. 3 (1978) pp. 597-603. |
Winston, Anthony and McLaughline, Glenn R., “Hydroxamic Acid Polymers. II. Design of a Polymeric Chelating Agent for Iron,” Journal of Polymer Science, vol. 14 (1976) pp. 2155-2165. |
Written Opinion dated Apr. 27, 2006 for PCT/US2005/039366. |
Xiao, Youchang et al., “Effects of Thermal Treatments and Dendrimers Chemical Structures on the Properties of Highly Surface Cross-Linked Polyimide Films” Ind. Eng. Chem. Res., 44 (2005) 3059-3067. |
Xiuru Li, et al., “Synthesis and Characterization of Hyperbranched Poly(ester amide)s from Commercially Available Dicarboxylic Acids and Multihydroxyl Primary Amines” Macromolecules, 39 (2006) 7889-7899. |
Yan, Deyue, “Hyperbranched Polymers Made from A2 and BB′2 Type Monomers. 1. Polyaddition of 1-(2-Aminoethyl)piperazine to Divinyl Sulfone” Macromolecules (2000), 33(21), 7693-7699. |
Zabutaya, F.I., et al .. “Proton NMR spectroscopic study of the reaction of epichlorahydrin with allyamine,” Uzb. Chim. Zh., vol. 3 (1984) pp. 23-27. (English Abstract, see XP 002025287). |
Zhuzhu, “New Drug to Decrease the Phosphorous in Blood—Sevelamer Hydrochloride”, Chinese Pharmaceutical Journal, 1999, 34:7, 496-497 [English translation provided]. |
Number | Date | Country | |
---|---|---|---|
20170202872 A1 | Jul 2017 | US |
Number | Date | Country | |
---|---|---|---|
60174227 | Jan 2000 | US | |
60160258 | Oct 1999 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14481071 | Sep 2014 | US |
Child | 15420896 | US | |
Parent | 13467448 | May 2012 | US |
Child | 14481071 | US | |
Parent | 12461143 | Aug 2009 | US |
Child | 13467448 | US | |
Parent | 11196799 | Aug 2005 | US |
Child | 12461143 | US | |
Parent | 10785322 | Feb 2004 | US |
Child | 11196799 | US | |
Parent | 09691429 | Oct 2000 | US |
Child | 10785322 | US |